{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:08:44Z","timestamp":1793210924023,"version":"4.5.0"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,16]],"date-time":"2024-07-16T00:00:00Z","timestamp":1721088000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100016198","name":"Idorsia Pharmaceuticals Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100016198","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Sleep Medicine"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.sleep.2024.07.019","type":"journal-article","created":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T22:28:25Z","timestamp":1721773705000},"page":"315-325","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Dose-response of daridorexant in insomnia disorder: An analysis of Phase 2 and 3 studies"],"prefix":"10.1016","volume":"121","author":[{"given":"Pierre-Philippe","family":"Luyet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William V.","family":"McCall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio L.A.","family":"Bassetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"Braunstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johann","family":"Laurent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Olivieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Hedner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.sleep.2024.07.019_bib1","series-title":"Report from dose finding workshop","first-page":"4","year":"2015"},{"key":"10.1016\/j.sleep.2024.07.019_bib3","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1001\/jama.2013.282542","article-title":"Scientific and regulatory reasons for delay and denial of FDA approval of initial applications for new drugs, 2000-2012","volume":"311","author":"Sacks","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.sleep.2024.07.019_bib4","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1002\/pds.744","article-title":"Postmarketing drug dosage changes of 499 FDA-approved new molecular entities, 1980-1999","volume":"11","author":"Cross","year":"2002","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.sleep.2024.07.019_bib5","doi-asserted-by":"crossref","first-page":"151","DOI":"10.2147\/NSS.S134864","article-title":"Short- and long-term health consequences of sleep disruption","volume":"9","author":"Medic","year":"2017","journal-title":"Nat Sci Sleep"},{"key":"10.1016\/j.sleep.2024.07.019_bib7","doi-asserted-by":"crossref","first-page":"307","DOI":"10.5664\/jcsm.6470","article-title":"Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults: an American Academy of Sleep Medicine Clinical Practice Guideline","volume":"13","author":"Sateia","year":"2017","journal-title":"J Clin Sleep Med"},{"key":"10.1016\/j.sleep.2024.07.019_bib8","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1186\/s12889-023-16329-9","article-title":"The burden of untreated insomnia disorder in a sample of 1 million adults: a cohort study","volume":"23","author":"Grandner","year":"2023","journal-title":"BMC Publ Health"},{"key":"10.1016\/j.sleep.2024.07.019_bib9","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1007\/s12264-007-0035-9","article-title":"Objective and subjective measures for sleep disorders","volume":"23","author":"Zhang","year":"2007","journal-title":"Neurosci Bull"},{"key":"10.1016\/j.sleep.2024.07.019_bib12","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s40265-022-01699-y","article-title":"Daridorexant: first approval","volume":"82","author":"Markham","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.sleep.2024.07.019_bib13","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1002\/cpt.1046","article-title":"Accelerated development of the dual orexin receptor antagonist ACT-541468: integration of a microtracer in a first-in-human study","volume":"104","author":"Muehlan","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.sleep.2024.07.019_bib14","doi-asserted-by":"crossref","first-page":"e2222","DOI":"10.1212\/WNL.0000000000009475","article-title":"Daridorexant, a new dual orexin receptor antagonist, in elderly subjects with insomnia disorder","volume":"94","author":"Zammit","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.sleep.2024.07.019_bib15","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1002\/ana.25680","article-title":"Daridorexant, a new dual orexin receptor antagonist to treat insomnia disorder","volume":"87","author":"Dauvilliers","year":"2020","journal-title":"Ann Neurol"},{"key":"10.1016\/j.sleep.2024.07.019_bib16","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S1474-4422(21)00436-1","article-title":"Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials","volume":"21","author":"Mignot","year":"2022","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.sleep.2024.07.019_bib20","series-title":"Diagnostic and statistical manual of mental disorders: DSM-5","year":"2013"},{"key":"10.1016\/j.sleep.2024.07.019_bib21","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s40263-022-00980-8","article-title":"Long-term safety and tolerability of daridorexant in patients with insomnia disorder","volume":"37","author":"Kunz","year":"2023","journal-title":"CNS Drugs"},{"key":"10.1016\/j.sleep.2024.07.019_bib22","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1093\/sleep\/34.5.601","article-title":"The Insomnia Severity Index: psychometric indicators to detect insomnia cases and evaluate treatment response","volume":"34","author":"Morin","year":"2011","journal-title":"Sleep"},{"key":"10.1016\/j.sleep.2024.07.019_bib24","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s40271-020-00474-z","article-title":"Development and validation of the insomnia daytime symptoms and Impacts questionnaire (IDSIQ)","volume":"14","author":"Hudgens","year":"2021","journal-title":"Patient"},{"key":"10.1016\/j.sleep.2024.07.019_bib25","series-title":"Patient-reported outcome measures: use in medical product development to support labeling claims","article-title":"Guidance for industry","year":"2009"},{"key":"10.1016\/j.sleep.2024.07.019_bib26","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s12874-016-0189-0","article-title":"Dose-response meta-analysis of differences in means","volume":"16","author":"Crippa","year":"2016","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.sleep.2024.07.019_bib27","first-page":"133","article-title":"Meaningful within-patient change in subjective total sleep time in patients with insomnia disorder: an analysis of the Sleep Diary Questionnaire using data from open-label and phase III clinical trials","volume":"38","author":"Phillips-Beyer","year":"2024","journal-title":"Pharmaceut Med"},{"key":"10.1016\/j.sleep.2024.07.019_bib28","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.biopsych.2014.10.003","article-title":"Suvorexant in patients with insomnia: results from two 3-month randomized controlled clinical trials","volume":"79","author":"Herring","year":"2016","journal-title":"Biol Psychiatr"},{"key":"10.1016\/j.sleep.2024.07.019_bib29","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1175372","article-title":"Different doses of dual orexin receptor antagonists in primary insomnia: a Bayesian network analysis","volume":"14","author":"Xue","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.sleep.2024.07.019_bib30","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/S0140-6736(22)00878-9","article-title":"Comparative effects of pharmacological interventions for the acute and long-term management of insomnia disorder in adults: a systematic review and network meta-analysis","volume":"400","author":"De Crescenzo","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.sleep.2024.07.019_bib31","article-title":"Demonstrating substantial evidence of effectiveness for human drug and biological products","year":"2019","journal-title":"Draft Guid Indust"},{"key":"10.1016\/j.sleep.2024.07.019_bib32","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1002\/sim.6052","article-title":"Model-based dose finding under model uncertainty using general parametric models","volume":"33","author":"Pinheiro","year":"2014","journal-title":"Stat Med"},{"key":"10.1016\/j.sleep.2024.07.019_bib33","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1111\/j.1541-0420.2005.00344.x","article-title":"Combining multiple comparisons and modeling techniques in dose-response studies","volume":"61","author":"Bretz","year":"2005","journal-title":"Biometrics"},{"key":"10.1016\/j.sleep.2024.07.019_bib35","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1002\/psp4.12877","article-title":"Population pharmacokinetic modeling of daridorexant, a novel dual orexin receptor antagonist","volume":"12","author":"Krause","year":"2022","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.sleep.2024.07.019_bib36","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1007\/s40266-022-00977-4","article-title":"Efficacy and safety of daridorexant in older and younger adults with insomnia disorder: a secondary analysis of a randomised placebo-controlled trial","volume":"39","author":"Fietze","year":"2022","journal-title":"Drugs Aging"}],"container-title":["Sleep Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S138994572400337X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S138994572400337X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T10:59:58Z","timestamp":1723719598000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S138994572400337X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":27,"alternative-id":["S138994572400337X"],"URL":"https:\/\/doi.org\/10.1016\/j.sleep.2024.07.019","relation":{},"ISSN":["1389-9457"],"issn-type":[{"value":"1389-9457","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dose-response of daridorexant in insomnia disorder: An analysis of Phase 2 and 3 studies","name":"articletitle","label":"Article Title"},{"value":"Sleep Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.sleep.2024.07.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}